What’s the current market cap for Altimmune stock?

Altimmune (ALT) has a market cap of $510m as of June 17, 2026.

What is the P/E ratio for Altimmune stock?

The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of June 17, 2026.

Does Altimmune stock pay dividends?

No, Altimmune (ALT) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Altimmune dividend payment date?

Altimmune (ALT) stock does not pay dividends to its shareholders.

What is the beta indicator for Altimmune?

Altimmune (ALT) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Altimmune stock | $ALT Share Price

13:30

15:10

16:45

18:25

20:00

About Altimmune

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Ticker

$ALT

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Gaithersburg, United States

Website

altimmune.com

Altimmune Metrics

BasicAdvanced

$510m

-$0.91

0.17

What the Analysts think about Altimmune

Analyst ratings (Buy, Hold, Sell) for Altimmune stock.

Bulls say / Bears say

The FDA granted Breakthrough Therapy Designation for pemvidutide in MASH on January 5, 2026, speeding up its development and giving it a priority review pathway (Reuters via TradingView)

Altimmune’s oversubscribed $225 million public offering in April 2026 increased its cash position to $535 million as of April 30, 2026, ensuring strong funding for its lead programs (Investing.com)

48-week Phase 2b results showed lasting weight loss and notable improvement in non-invasive liver fibrosis measures, supporting the move to Phase 3 trials (Reuters)

Despite improvements detected by non-invasive methods, the lack of biopsy-confirmed outcomes in the 48-week IMPACT trial results disappointed investors and resulted in a subdued market response (Reuters)

Pemvidutide goes up against leading GLP-1 therapies from Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Mounjaro, Zepbound), which could restrict its market adoption for obesity-related liver diseases (Reuters)

The topline data from the RECLAIM Phase 2 trial in alcohol use disorder is not expected until Q3 2026, leaving a significant gap without major news that could add to stock price volatility (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Altimmune Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Altimmune Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALT

Capital at risk

Market closed

Upcoming events

No upcoming events